Supplementary Materials from Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in <i>EGFR</i>-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors

Abstract

<p>Supplementary Table 1. Overview of the individual survival times, MGMT promoter methylation status and results of EGFRvIII testing by immunohistochemistry (IHC) or reverse transcription-PCR (RT-PCR) in primary tumors (PT) and recurrent tumors (RT) of 106 patients with newly diagnosed EGFR-amplified glioblastomas, IDH-wildtype. PFS, progression-free survival; OS, overall survival; n.d., not determined; * deceased patients; ** no progression documented; {section sign} excluded for Kaplan-Meier analyses because EGFRvIII was determined at second recurrence. Supplementary Table 2. Overview of individual survival times, MGMT promoter methylation status and results of EGFRvIII testing by immunohistochemistry (IHC) or reverse transcription-PCR (RT-PCR) in primary tumors (PT) and recurrent tumors (RT) of 33 patients with newly diagnosed IDH-wildtype, EGFR-non-amplified glioblastomas. N.d., not determined. * Deceased patients. Supplementary Table 3. Overview of the EGFR single nucleotide variants (SNVs) detected by next generation sequencing (NGS) in primary (PT) and recurrent (RT) glioblastomas of 27 patients. Mutant allele frequencies in percent are provided for each single nucleotide variant (SNV). Supplementary Table 4. Overview of the validation cohort of 150 TCGA patients with IDH-wildtype glioblastoma (GBM). Supplementary Figure 1. Demonstration of regional heterogeneity of EGFRvIII expression in an EGFR-amplified primary glioblastoma, IDH-wildtype (patient 96). Supplementary Figure 2. EGFRvIII expression and MGMT promoter methylation status and survival outcome in 77 patients with EGFR-amplified glioblastomas treated with radiotherapy and temozolomide chemotherapy. Supplementary Figure 3. Survival of patients with EGFR-amplified glioblastomas, IDH-wildtype, according to the EGFRvIII status in the subgroups of patients who received second surgery (52 patients) or did not receive second surgery (54 patients). Supplementary Figure 4. Survival of 27 German Glioma Network (GGN) patients with glioblastoma, IDH-wildtype, according to presence (9 patients) or absence (18 patients) of at least one EGFR single nucleotide variant (SNV) as detected by NGS of the EGFR coding sequence. Supplementary Figure 5. Survival of TCGA patients with glioblastoma, IDH-wildtype, according to EGFR amplification, presence of at least one EGFR single nucleotide variant (SNV), and EGFRvIII positivity.</p>